You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lutetium-177

Showing 1 - 25 of 201
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

Completed
  • Neuroendocrine Tumor
  • Lutetium-177 DOTATATE
  • Houston, Texas
    Excel Diagnostics & Nuclear Oncology Center
Apr 16, 2023

Advanced Malignant Tumor Trial in Beijing ([ Lu-177]-Catalase)

Recruiting
  • Advanced Malignant Neoplasm
  • [ Lu-177]-Catalase
  • Beijing, Beijing, China
    Zhi Yang
Aug 2, 2023

Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma Trial in Nijmegen (Lutetium-177-PSMA-I&T)

Recruiting
  • Salivary Gland Cancer
  • +2 more
  • Nijmegen, Gelderland, Netherlands
    Radboudumc
Oct 27, 2022

Prostate Cancer Trial (AAA617)

Not yet recruiting
  • Prostate Cancer
  • (no location specified)
Mar 27, 2023

Advanced Gastroenteropancreatic Neuroendocrine Tumor Trial (Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide,

Not yet recruiting
  • Advanced Gastroenteropancreatic Neuroendocrine Tumor
  • Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
  • long-acting Octreotide.
  • (no location specified)
May 22, 2023

Prostatic Tumor Trial (AAA617, AAA517, Piflufolastat F 18)

Not yet recruiting
  • Prostatic Neoplasm
  • (no location specified)
Apr 27, 2023

Oligometastatic Prostate Cancer (OMPC) Trial (AAA617)

Not yet recruiting
  • Oligometastatic Prostate Cancer (OMPC)
  • (no location specified)
Jul 3, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (AAA617, 68Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 16, 2023

Metastatic Castration-resistant Prostate Cancer, mCRPC, Prostate Cancer Trial in Melbourne (Lutetium-177 PSMA-I&T, Radium-223)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • +2 more
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Sep 26, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Cabozantinib)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Salt Lake City, Utah
    Huntsman Cancer Institute at University of Utah
Nov 10, 2022

Neuroendocrine Tumor Trial in United States (Lutetium Lu 177 Dotatate, Peposertib)

Recruiting
  • Neuroendocrine Neoplasm
  • Biospecimen Collection
  • +4 more
  • Duarte, California
  • +3 more
Jan 12, 2023

Metastatic Neuroendocrine Tumor Trial (Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate)

Not yet recruiting
  • Metastatic Neuroendocrine Tumor
  • Biospecimen Collection
  • +4 more
  • (no location specified)
Feb 10, 2023

Neuroendocrine Carcinoma Trial in London (Lu-DOTA-TATE)

Active, not recruiting
  • Neuroendocrine Carcinoma
  • Lu-DOTA-TATE
  • London, Ontario, Canada
    London Health Sciences Centre
Apr 5, 2022

Prostate Cancer Trial (Lutetium Lu 177 JH020002 Injection)

Not yet recruiting
  • Prostate Cancer
  • Lutetium Lu 177 JH020002 Injection
  • (no location specified)
Nov 14, 2023

Metastatic Malignant Tumor in the Viscera, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic

Not yet recruiting
  • Metastatic Malignant Neoplasm in the Viscera
  • +4 more
  • Lutetium Lu 177 Dotatate
  • (no location specified)
Jan 25, 2023

Breast Cancer Stage IV Trial in Iowa City, New Delhi, Chandigarh (Lutetium-177-PEG-avß3-IAC)

Not yet recruiting
  • Breast Cancer Stage IV
  • Iowa City, Iowa
  • +2 more
Jun 7, 2022

Neuroendocrine Tumors Trial in Beijing (Lutetium[177Lu] Oxodotreotide Injection)

Not yet recruiting
  • Neuroendocrine Tumors
  • Lutetium[177Lu] Oxodotreotide Injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
May 30, 2023

Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Tumor, Stage III Pancreatic Neuroendocrine Tumor AJCC v8 Trial

Not yet recruiting
  • Metastatic Pancreatic Neuroendocrine Tumor
  • +4 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Jan 14, 2023

Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco

Not yet recruiting
  • Castrate Resistant Prostate Cancer
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Mar 1, 2023

Metastatic Castration-resistant Prostate Cancer Trial (ONC-392, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • ONC-392
  • lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.
  • (no location specified)
Dec 27, 2022

Advanced Lung Carcinoid Tumor, Functioning Lung Carcinoid Tumor, Locally Advanced Lung Neuroendocrine Tumor Trial in Boston,

Recruiting
  • Advanced Lung Carcinoid Tumor
  • +11 more
  • Boston, Massachusetts
  • +1 more
Jul 19, 2022

Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma Trial in Los Angeles (drug,

Not yet recruiting
  • Oligometastatic Prostate Carcinoma
  • +3 more
  • Lutetium Lu-177 PNT2002
  • +2 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Aug 15, 2022

Metastatic Digestive System Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor Trial in United States (Lutetium Lu 177

Recruiting
  • Metastatic Digestive System Neuroendocrine Neoplasm
  • Metastatic Neuroendocrine Tumor
  • Phoenix, Arizona
  • +10 more
Aug 23, 2022

Prostate Cancer Trial in Amsterdam, Groningen, Nijmegen (177Lu-PSMA-617)

Recruiting
  • Prostate Cancer
  • Amsterdam, Netherlands
  • +3 more
Oct 17, 2021

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Seattle

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Biopsy
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Nov 17, 2023